| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| C-Reactive Protein | 135 | 2023 | 3812 | 4.800 |
Why?
|
| Editorial Policies | 17 | 2018 | 456 | 4.690 |
Why?
|
| Clinical Laboratory Techniques | 17 | 2017 | 748 | 3.150 |
Why?
|
| Chemistry, Clinical | 11 | 2018 | 64 | 2.730 |
Why?
|
| Specimen Handling | 10 | 2013 | 707 | 2.350 |
Why?
|
| Disclosure | 10 | 2015 | 738 | 2.030 |
Why?
|
| Clinical Medicine | 5 | 2012 | 145 | 1.790 |
Why?
|
| Cholesterol, LDL | 42 | 2023 | 2374 | 1.690 |
Why?
|
| Immunoassay | 28 | 2015 | 746 | 1.650 |
Why?
|
| Interleukin-6 | 42 | 2023 | 3208 | 1.400 |
Why?
|
| Publishing | 6 | 2018 | 833 | 1.360 |
Why?
|
| Coronary Disease | 43 | 2011 | 5917 | 1.350 |
Why?
|
| Periodicals as Topic | 11 | 2012 | 1462 | 1.300 |
Why?
|
| Cholesterol | 36 | 2023 | 2902 | 1.160 |
Why?
|
| Cholesterol, HDL | 35 | 2020 | 1808 | 1.110 |
Why?
|
| Journalism, Medical | 3 | 2012 | 73 | 1.110 |
Why?
|
| Lipoproteins | 23 | 2020 | 881 | 1.080 |
Why?
|
| Lipids | 36 | 2016 | 3326 | 1.080 |
Why?
|
| Art | 2 | 2016 | 64 | 1.000 |
Why?
|
| Gonadal Steroid Hormones | 16 | 2016 | 701 | 0.980 |
Why?
|
| Apolipoproteins | 19 | 2008 | 319 | 0.960 |
Why?
|
| Lipoprotein(a) | 18 | 2023 | 479 | 0.960 |
Why?
|
| Biomedical Research | 10 | 2018 | 3418 | 0.950 |
Why?
|
| Reagent Kits, Diagnostic | 14 | 2015 | 238 | 0.940 |
Why?
|
| Cardiovascular Diseases | 67 | 2023 | 15399 | 0.920 |
Why?
|
| Lead | 5 | 2024 | 878 | 0.920 |
Why?
|
| Arteriosclerosis | 15 | 2004 | 1055 | 0.900 |
Why?
|
| Homocysteine | 15 | 2022 | 638 | 0.860 |
Why?
|
| Conflict of Interest | 4 | 2011 | 548 | 0.840 |
Why?
|
| Blood Chemical Analysis | 4 | 2016 | 437 | 0.820 |
Why?
|
| Peer Review | 3 | 2019 | 217 | 0.780 |
Why?
|
| Hyperlipidemias | 13 | 2020 | 772 | 0.770 |
Why?
|
| Learning | 2 | 2023 | 1739 | 0.760 |
Why?
|
| Inflammation | 47 | 2020 | 10718 | 0.750 |
Why?
|
| Research Support as Topic | 5 | 2011 | 697 | 0.730 |
Why?
|
| Hair | 1 | 2024 | 497 | 0.720 |
Why?
|
| Fasting | 24 | 2016 | 1599 | 0.710 |
Why?
|
| Clinical Chemistry Tests | 5 | 2008 | 59 | 0.700 |
Why?
|
| Heptanoic Acids | 12 | 2012 | 344 | 0.700 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 18 | 2023 | 3227 | 0.680 |
Why?
|
| Reference Values | 31 | 2016 | 4919 | 0.680 |
Why?
|
| Nephelometry and Turbidimetry | 20 | 2007 | 91 | 0.670 |
Why?
|
| Troponin I | 13 | 2012 | 632 | 0.640 |
Why?
|
| Industry | 5 | 2011 | 361 | 0.630 |
Why?
|
| Laboratories | 6 | 2023 | 460 | 0.620 |
Why?
|
| Chromatography, High Pressure Liquid | 14 | 2005 | 1539 | 0.610 |
Why?
|
| Humans | 455 | 2024 | 758406 | 0.610 |
Why?
|
| Education, Professional | 1 | 2018 | 51 | 0.610 |
Why?
|
| Sex Hormone-Binding Globulin | 17 | 2016 | 546 | 0.610 |
Why?
|
| Intercellular Adhesion Molecule-1 | 21 | 2011 | 1125 | 0.600 |
Why?
|
| Serum Amyloid A Protein | 17 | 2013 | 127 | 0.590 |
Why?
|
| Adiponectin | 15 | 2023 | 1114 | 0.570 |
Why?
|
| Pravastatin | 12 | 2012 | 392 | 0.560 |
Why?
|
| Peripheral Vascular Diseases | 9 | 2008 | 488 | 0.550 |
Why?
|
| Diagnostic Tests, Routine | 5 | 2021 | 787 | 0.550 |
Why?
|
| Apolipoproteins B | 15 | 2020 | 385 | 0.550 |
Why?
|
| Medicine | 2 | 2023 | 942 | 0.540 |
Why?
|
| Leptin | 12 | 2023 | 1591 | 0.540 |
Why?
|
| Troponin T | 15 | 2012 | 761 | 0.530 |
Why?
|
| Triglycerides | 29 | 2016 | 2451 | 0.520 |
Why?
|
| Acute Coronary Syndrome | 13 | 2023 | 2180 | 0.520 |
Why?
|
| Drug Industry | 3 | 2010 | 787 | 0.520 |
Why?
|
| Pyrroles | 12 | 2012 | 1130 | 0.510 |
Why?
|
| Hypercholesterolemia | 12 | 2015 | 1138 | 0.510 |
Why?
|
| Myocardial Infarction | 42 | 2023 | 11424 | 0.500 |
Why?
|
| Portraits as Topic | 1 | 2015 | 32 | 0.500 |
Why?
|
| Estradiol | 14 | 2014 | 1933 | 0.490 |
Why?
|
| Angina, Unstable | 13 | 2008 | 887 | 0.480 |
Why?
|
| Testosterone | 16 | 2014 | 2471 | 0.470 |
Why?
|
| Lead Poisoning | 5 | 2013 | 321 | 0.470 |
Why?
|
| C-Peptide | 11 | 2015 | 433 | 0.460 |
Why?
|
| Troponin | 11 | 2010 | 500 | 0.450 |
Why?
|
| Photography | 1 | 2016 | 530 | 0.440 |
Why?
|
| Case-Control Studies | 68 | 2023 | 22029 | 0.430 |
Why?
|
| Middle Aged | 238 | 2019 | 219568 | 0.430 |
Why?
|
| Risk Factors | 130 | 2023 | 73809 | 0.430 |
Why?
|
| Diabetic Angiopathies | 10 | 2009 | 802 | 0.420 |
Why?
|
| Fetal Blood | 7 | 2012 | 1343 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 34 | 2013 | 12075 | 0.410 |
Why?
|
| Schools, Medical | 1 | 2019 | 877 | 0.410 |
Why?
|
| Ultracentrifugation | 7 | 2004 | 183 | 0.400 |
Why?
|
| Fibrinogen | 10 | 2023 | 883 | 0.380 |
Why?
|
| Information Services | 1 | 2012 | 235 | 0.380 |
Why?
|
| Publication Bias | 2 | 2010 | 161 | 0.380 |
Why?
|
| Anticholesteremic Agents | 12 | 2011 | 963 | 0.380 |
Why?
|
| Busulfan | 2 | 2005 | 258 | 0.370 |
Why?
|
| Pancreatic Neoplasms | 9 | 2023 | 5349 | 0.370 |
Why?
|
| Female | 252 | 2023 | 390323 | 0.370 |
Why?
|
| Atherosclerosis | 9 | 2023 | 3401 | 0.360 |
Why?
|
| Dextran Sulfate | 5 | 2000 | 255 | 0.360 |
Why?
|
| Chemistry | 1 | 2010 | 348 | 0.360 |
Why?
|
| Teaching | 1 | 2018 | 1168 | 0.360 |
Why?
|
| Mass Spectrometry | 4 | 2014 | 2189 | 0.360 |
Why?
|
| Sensitivity and Specificity | 33 | 2015 | 14641 | 0.360 |
Why?
|
| Research Design | 8 | 2021 | 6157 | 0.360 |
Why?
|
| Diagnosis | 3 | 2017 | 156 | 0.350 |
Why?
|
| Research Report | 2 | 2021 | 367 | 0.350 |
Why?
|
| Male | 229 | 2023 | 358747 | 0.350 |
Why?
|
| Blood Proteins | 3 | 2013 | 1173 | 0.350 |
Why?
|
| Postmenopause | 17 | 2013 | 2509 | 0.340 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 9 | 2009 | 418 | 0.340 |
Why?
|
| Prospective Studies | 90 | 2023 | 54137 | 0.340 |
Why?
|
| Science | 1 | 2012 | 239 | 0.340 |
Why?
|
| Antibodies, Heterophile | 2 | 2008 | 128 | 0.340 |
Why?
|
| Natriuretic Peptide, Brain | 10 | 2013 | 1704 | 0.340 |
Why?
|
| Albuminuria | 9 | 2015 | 650 | 0.340 |
Why?
|
| Peer Review, Research | 1 | 2013 | 340 | 0.340 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 11 | 2016 | 346 | 0.330 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 14 | 2013 | 691 | 0.330 |
Why?
|
| Financing, Organized | 1 | 2010 | 204 | 0.330 |
Why?
|
| Macular Degeneration | 3 | 2007 | 1001 | 0.320 |
Why?
|
| Reference Standards | 12 | 2015 | 1003 | 0.320 |
Why?
|
| Chromatography, Gas | 5 | 1998 | 151 | 0.320 |
Why?
|
| Receptors, Leptin | 5 | 2023 | 350 | 0.310 |
Why?
|
| Academies and Institutes | 1 | 2011 | 319 | 0.310 |
Why?
|
| Autoanalysis | 7 | 2003 | 71 | 0.310 |
Why?
|
| Scientific Misconduct | 3 | 2018 | 74 | 0.310 |
Why?
|
| Adult | 152 | 2023 | 219935 | 0.310 |
Why?
|
| Students | 1 | 2018 | 1734 | 0.310 |
Why?
|
| Regression Analysis | 19 | 2008 | 6354 | 0.310 |
Why?
|
| Goiter | 1 | 2008 | 87 | 0.300 |
Why?
|
| Risk | 32 | 2015 | 9599 | 0.300 |
Why?
|
| Angina Pectoris | 6 | 2007 | 958 | 0.300 |
Why?
|
| Amides | 5 | 2013 | 447 | 0.300 |
Why?
|
| Inflammation Mediators | 8 | 2013 | 1878 | 0.300 |
Why?
|
| Physical Endurance | 4 | 1999 | 362 | 0.290 |
Why?
|
| Drug Monitoring | 7 | 2005 | 960 | 0.290 |
Why?
|
| Insulin-Like Growth Factor I | 7 | 2014 | 1927 | 0.280 |
Why?
|
| Aged | 136 | 2018 | 168218 | 0.280 |
Why?
|
| Predictive Value of Tests | 34 | 2013 | 15225 | 0.270 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2010 | 791 | 0.270 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 15 | 2012 | 3801 | 0.270 |
Why?
|
| Risk Assessment | 36 | 2013 | 23884 | 0.270 |
Why?
|
| Endothelium, Vascular | 12 | 2015 | 4429 | 0.270 |
Why?
|
| Peptide Mapping | 1 | 2006 | 262 | 0.270 |
Why?
|
| Thyrotropin | 2 | 2008 | 832 | 0.260 |
Why?
|
| Magnesium | 3 | 2000 | 809 | 0.260 |
Why?
|
| Research | 4 | 2014 | 1976 | 0.260 |
Why?
|
| Thrombolytic Therapy | 8 | 2010 | 2060 | 0.260 |
Why?
|
| Heart Diseases | 6 | 2006 | 2782 | 0.250 |
Why?
|
| Adipokines | 3 | 2023 | 311 | 0.250 |
Why?
|
| Blood Pressure | 17 | 2010 | 8451 | 0.250 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2014 | 415 | 0.250 |
Why?
|
| Clinical Trials as Topic | 6 | 2014 | 7985 | 0.250 |
Why?
|
| Double-Blind Method | 24 | 2023 | 12262 | 0.250 |
Why?
|
| Lipoproteins, HDL | 6 | 2009 | 664 | 0.240 |
Why?
|
| Myoglobin | 7 | 2008 | 159 | 0.240 |
Why?
|
| Terminology as Topic | 3 | 2015 | 1533 | 0.240 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2005 | 48 | 0.240 |
Why?
|
| Program Development | 1 | 2011 | 1298 | 0.240 |
Why?
|
| Lipid Peroxidation | 4 | 2007 | 271 | 0.240 |
Why?
|
| Hypertriglyceridemia | 4 | 2022 | 293 | 0.240 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 401 | 0.240 |
Why?
|
| Cell Adhesion Molecules | 7 | 2015 | 1600 | 0.240 |
Why?
|
| Adiposity | 6 | 2016 | 1858 | 0.230 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 266 | 0.230 |
Why?
|
| Iron | 8 | 2008 | 1786 | 0.230 |
Why?
|
| Bibliometrics | 1 | 2008 | 349 | 0.230 |
Why?
|
| Cotinine | 1 | 2004 | 203 | 0.230 |
Why?
|
| Obesity | 21 | 2016 | 12870 | 0.230 |
Why?
|
| Entrepreneurship | 2 | 2015 | 23 | 0.230 |
Why?
|
| Apolipoproteins A | 5 | 2006 | 95 | 0.220 |
Why?
|
| Registries | 3 | 2017 | 8175 | 0.220 |
Why?
|
| Guidelines as Topic | 7 | 2014 | 1386 | 0.220 |
Why?
|
| Quality Control | 8 | 2015 | 825 | 0.220 |
Why?
|
| Clotrimazole | 4 | 1996 | 76 | 0.220 |
Why?
|
| Antioxidants | 9 | 2004 | 1662 | 0.220 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2003 | 86 | 0.220 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 6 | 2005 | 1651 | 0.220 |
Why?
|
| Adipose Tissue | 6 | 2019 | 3299 | 0.220 |
Why?
|
| Famous Persons | 1 | 2024 | 109 | 0.210 |
Why?
|
| Blood Glucose | 14 | 2015 | 6346 | 0.210 |
Why?
|
| Electrocoagulation | 1 | 2003 | 152 | 0.210 |
Why?
|
| Acute-Phase Reaction | 2 | 2001 | 91 | 0.210 |
Why?
|
| Insulin | 15 | 2016 | 6578 | 0.210 |
Why?
|
| Mass Screening | 6 | 2008 | 5427 | 0.210 |
Why?
|
| Chylothorax | 1 | 2003 | 83 | 0.210 |
Why?
|
| Razoxane | 3 | 2012 | 43 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 7 | 2015 | 7378 | 0.210 |
Why?
|
| Aldosterone | 4 | 2013 | 866 | 0.210 |
Why?
|
| Body Mass Index | 36 | 2016 | 12876 | 0.210 |
Why?
|
| Vitamin E | 8 | 2009 | 870 | 0.210 |
Why?
|
| Receptors, Tumor Necrosis Factor | 9 | 2008 | 584 | 0.210 |
Why?
|
| Myocardial Reperfusion | 2 | 2001 | 337 | 0.210 |
Why?
|
| Multivariate Analysis | 30 | 2015 | 12096 | 0.200 |
Why?
|
| Hypolipidemic Agents | 3 | 2020 | 609 | 0.200 |
Why?
|
| Uremia | 1 | 2003 | 201 | 0.200 |
Why?
|
| Postprandial Period | 4 | 2016 | 314 | 0.200 |
Why?
|
| Hypertension | 18 | 2015 | 8499 | 0.200 |
Why?
|
| Lipoproteins, LDL | 5 | 2009 | 640 | 0.200 |
Why?
|
| Dietary Fats | 8 | 2005 | 1991 | 0.200 |
Why?
|
| Running | 3 | 2006 | 483 | 0.200 |
Why?
|
| CD40 Ligand | 4 | 2008 | 519 | 0.200 |
Why?
|
| Cardiomyopathies | 5 | 2012 | 1944 | 0.200 |
Why?
|
| District of Columbia | 6 | 2000 | 160 | 0.190 |
Why?
|
| Cardiology | 1 | 2013 | 1667 | 0.190 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 617 | 0.190 |
Why?
|
| Sports | 2 | 1999 | 699 | 0.190 |
Why?
|
| Swimming | 2 | 1999 | 206 | 0.190 |
Why?
|
| Colorectal Neoplasms | 10 | 2016 | 6852 | 0.190 |
Why?
|
| Ferritins | 5 | 2008 | 597 | 0.190 |
Why?
|
| beta 2-Microglobulin | 3 | 1994 | 328 | 0.190 |
Why?
|
| Follow-Up Studies | 45 | 2019 | 39059 | 0.190 |
Why?
|
| Sex Factors | 17 | 2012 | 10504 | 0.190 |
Why?
|
| Alcohol Drinking | 12 | 2009 | 4018 | 0.190 |
Why?
|
| Bicycling | 2 | 1999 | 176 | 0.190 |
Why?
|
| Myelin P2 Protein | 1 | 2000 | 20 | 0.180 |
Why?
|
| History, 21st Century | 3 | 2016 | 1573 | 0.180 |
Why?
|
| Transferrin | 7 | 2008 | 284 | 0.180 |
Why?
|
| Doxorubicin | 6 | 2012 | 2209 | 0.180 |
Why?
|
| Algorithms | 6 | 2013 | 13961 | 0.180 |
Why?
|
| Cardiotonic Agents | 2 | 2012 | 539 | 0.180 |
Why?
|
| Proteins | 3 | 2012 | 6026 | 0.180 |
Why?
|
| Peptide Fragments | 5 | 2013 | 5098 | 0.180 |
Why?
|
| United States | 47 | 2016 | 72136 | 0.180 |
Why?
|
| Resistin | 2 | 2013 | 172 | 0.180 |
Why?
|
| Echocardiography | 6 | 2012 | 4962 | 0.180 |
Why?
|
| Reproducibility of Results | 17 | 2015 | 20055 | 0.180 |
Why?
|
| History, 19th Century | 2 | 2015 | 720 | 0.180 |
Why?
|
| Kidney Failure, Chronic | 4 | 2008 | 2457 | 0.180 |
Why?
|
| Cohort Studies | 48 | 2013 | 41256 | 0.180 |
Why?
|
| Creatine Kinase | 7 | 2006 | 686 | 0.180 |
Why?
|
| Vitamin D | 4 | 2016 | 3283 | 0.170 |
Why?
|
| Feeding Behavior | 8 | 2016 | 3184 | 0.170 |
Why?
|
| Protoporphyrins | 2 | 2013 | 165 | 0.170 |
Why?
|
| Aspirin | 8 | 2016 | 3131 | 0.170 |
Why?
|
| Diet | 12 | 2016 | 8005 | 0.170 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2015 | 2239 | 0.170 |
Why?
|
| Fatty Acids, Omega-3 | 3 | 2023 | 1373 | 0.170 |
Why?
|
| Lipid Metabolism | 3 | 2016 | 1895 | 0.170 |
Why?
|
| Helicobacter pylori | 1 | 2023 | 376 | 0.170 |
Why?
|
| Body Composition | 5 | 2019 | 2416 | 0.170 |
Why?
|
| Helicobacter Infections | 1 | 2023 | 385 | 0.170 |
Why?
|
| Creatine Kinase, MB Form | 5 | 2008 | 202 | 0.170 |
Why?
|
| Apolipoproteins E | 5 | 1988 | 1436 | 0.170 |
Why?
|
| P-Selectin | 2 | 2002 | 597 | 0.160 |
Why?
|
| Electrocardiography | 7 | 2010 | 6363 | 0.160 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2012 | 1547 | 0.160 |
Why?
|
| Health Surveys | 8 | 2011 | 4064 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2015 | 4342 | 0.160 |
Why?
|
| Valine | 3 | 2013 | 408 | 0.160 |
Why?
|
| Sex Characteristics | 7 | 2016 | 2621 | 0.160 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 1999 | 104 | 0.160 |
Why?
|
| alpha-Cyclodextrins | 1 | 1998 | 12 | 0.160 |
Why?
|
| Coronary Artery Disease | 6 | 2013 | 6362 | 0.160 |
Why?
|
| Child, Preschool | 30 | 2012 | 42062 | 0.160 |
Why?
|
| Methylmalonic Acid | 1 | 1998 | 49 | 0.160 |
Why?
|
| Arginine | 3 | 2015 | 933 | 0.160 |
Why?
|
| Adenoma | 5 | 2009 | 2148 | 0.160 |
Why?
|
| Apolipoprotein A-I | 6 | 2006 | 294 | 0.150 |
Why?
|
| Communication | 1 | 2012 | 3846 | 0.150 |
Why?
|
| Bupivacaine | 2 | 2001 | 413 | 0.150 |
Why?
|
| National Health Programs | 1 | 2002 | 441 | 0.150 |
Why?
|
| Smoking | 20 | 2009 | 9051 | 0.150 |
Why?
|
| Carrier Proteins | 3 | 2001 | 4938 | 0.150 |
Why?
|
| Receptors, Adiponectin | 2 | 2023 | 81 | 0.150 |
Why?
|
| Prognosis | 28 | 2019 | 29557 | 0.150 |
Why?
|
| Prostatism | 2 | 2008 | 14 | 0.150 |
Why?
|
| Anesthetics, Local | 3 | 2001 | 1000 | 0.150 |
Why?
|
| Myocardial Contraction | 2 | 2003 | 1516 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2023 | 15773 | 0.150 |
Why?
|
| Adolescent | 35 | 2012 | 87892 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2012 | 675 | 0.150 |
Why?
|
| beta Carotene | 4 | 2004 | 523 | 0.150 |
Why?
|
| Urethritis | 1 | 2017 | 24 | 0.150 |
Why?
|
| Spectrophotometry, Ultraviolet | 4 | 2002 | 200 | 0.150 |
Why?
|
| Renin-Angiotensin System | 3 | 2013 | 733 | 0.150 |
Why?
|
| Ketoprofen | 1 | 1997 | 7 | 0.150 |
Why?
|
| Prostate-Specific Antigen | 4 | 2017 | 2528 | 0.150 |
Why?
|
| Biological Assay | 3 | 2014 | 626 | 0.150 |
Why?
|
| Propylene Glycols | 2 | 1994 | 90 | 0.140 |
Why?
|
| Hemoglobins | 2 | 2000 | 1519 | 0.140 |
Why?
|
| Human Growth Hormone | 3 | 2012 | 638 | 0.140 |
Why?
|
| Cystic Fibrosis | 2 | 1996 | 1274 | 0.140 |
Why?
|
| Logistic Models | 20 | 2015 | 13276 | 0.140 |
Why?
|
| Prostatitis | 1 | 2017 | 102 | 0.140 |
Why?
|
| Angola | 1 | 2016 | 17 | 0.140 |
Why?
|
| Child | 37 | 2013 | 79818 | 0.140 |
Why?
|
| Dehydroepiandrosterone Sulfate | 3 | 2008 | 240 | 0.140 |
Why?
|
| Aged, 80 and over | 33 | 2016 | 58683 | 0.140 |
Why?
|
| Statistics, Nonparametric | 9 | 2012 | 2850 | 0.140 |
Why?
|
| Authorship | 3 | 2009 | 281 | 0.140 |
Why?
|
| Infectious Mononucleosis | 1 | 2017 | 133 | 0.140 |
Why?
|
| Cross-Sectional Studies | 32 | 2023 | 25956 | 0.140 |
Why?
|
| Immunosuppressive Agents | 2 | 2002 | 4158 | 0.140 |
Why?
|
| Neopterin | 4 | 2012 | 56 | 0.140 |
Why?
|
| Stroke | 7 | 2023 | 9694 | 0.140 |
Why?
|
| Anthropometry | 7 | 2006 | 1347 | 0.140 |
Why?
|
| Nutrition Surveys | 7 | 2012 | 1716 | 0.140 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2008 | 226 | 0.140 |
Why?
|
| Paper | 1 | 2016 | 84 | 0.140 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 3 | 2006 | 125 | 0.140 |
Why?
|
| Ink | 1 | 2016 | 47 | 0.140 |
Why?
|
| Consensus | 4 | 2020 | 3099 | 0.130 |
Why?
|
| Vitamin A | 4 | 2004 | 613 | 0.130 |
Why?
|
| Digoxigenin | 1 | 1995 | 26 | 0.130 |
Why?
|
| Linear Models | 13 | 2013 | 5862 | 0.130 |
Why?
|
| Exercise | 9 | 2005 | 5788 | 0.130 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1995 | 69 | 0.130 |
Why?
|
| Infant, Newborn | 16 | 2012 | 26183 | 0.130 |
Why?
|
| Iron, Dietary | 3 | 2008 | 148 | 0.130 |
Why?
|
| Reactive Oxygen Species | 3 | 2009 | 2129 | 0.130 |
Why?
|
| Saponins | 1 | 1995 | 46 | 0.130 |
Why?
|
| Itraconazole | 1 | 1995 | 43 | 0.130 |
Why?
|
| Asparaginase | 1 | 1997 | 240 | 0.130 |
Why?
|
| Pyruvate Carboxylase Deficiency Disease | 1 | 1995 | 2 | 0.130 |
Why?
|
| Sirolimus | 1 | 2002 | 1533 | 0.130 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2010 | 431 | 0.130 |
Why?
|
| Educational Status | 1 | 2023 | 2513 | 0.130 |
Why?
|
| Chemical Precipitation | 4 | 2001 | 176 | 0.130 |
Why?
|
| Point-of-Care Systems | 2 | 2001 | 1201 | 0.130 |
Why?
|
| Radioligand Assay | 2 | 1992 | 366 | 0.120 |
Why?
|
| Dehydroepiandrosterone | 2 | 2008 | 257 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 3609 | 0.120 |
Why?
|
| Ibuprofen | 1 | 1996 | 229 | 0.120 |
Why?
|
| Neonatal Screening | 1 | 1999 | 594 | 0.120 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2008 | 1206 | 0.120 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2007 | 681 | 0.120 |
Why?
|
| Electrophoresis | 3 | 2002 | 234 | 0.120 |
Why?
|
| Creatinine | 9 | 2015 | 1892 | 0.120 |
Why?
|
| Hyperinsulinism | 3 | 2010 | 400 | 0.120 |
Why?
|
| Odds Ratio | 15 | 2015 | 9650 | 0.120 |
Why?
|
| Tetrazoles | 3 | 2013 | 899 | 0.120 |
Why?
|
| Life Style | 15 | 2009 | 3886 | 0.120 |
Why?
|
| Hematocrit | 2 | 2012 | 627 | 0.120 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2006 | 344 | 0.120 |
Why?
|
| Digoxin | 1 | 1995 | 246 | 0.120 |
Why?
|
| Cholecalciferol | 2 | 2023 | 549 | 0.120 |
Why?
|
| Urban Population | 3 | 2000 | 2025 | 0.120 |
Why?
|
| Ascorbic Acid | 3 | 2004 | 655 | 0.120 |
Why?
|
| E-Selectin | 6 | 2007 | 576 | 0.120 |
Why?
|
| Interleukin-1beta | 3 | 2022 | 996 | 0.120 |
Why?
|
| Proinsulin | 2 | 2005 | 135 | 0.120 |
Why?
|
| Thyroid Hormones | 2 | 2001 | 403 | 0.110 |
Why?
|
| Body Size | 3 | 2012 | 462 | 0.110 |
Why?
|
| Family Health | 1 | 1999 | 1257 | 0.110 |
Why?
|
| Neoplasms | 5 | 2013 | 22032 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 3 | 2006 | 1705 | 0.110 |
Why?
|
| Incidence | 21 | 2011 | 21272 | 0.110 |
Why?
|
| Prostatic Neoplasms | 10 | 2016 | 11336 | 0.110 |
Why?
|
| Genetic Variation | 7 | 2008 | 6548 | 0.110 |
Why?
|
| Chlamydia Infections | 1 | 2017 | 365 | 0.110 |
Why?
|
| Dietary Supplements | 7 | 2015 | 3387 | 0.110 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2015 | 219 | 0.110 |
Why?
|
| South Africa | 2 | 2016 | 1821 | 0.110 |
Why?
|
| Fumarates | 2 | 2013 | 131 | 0.110 |
Why?
|
| Time Factors | 19 | 2016 | 39872 | 0.110 |
Why?
|
| Cyclosporine | 1 | 1996 | 777 | 0.110 |
Why?
|
| Trans Fatty Acids | 2 | 2005 | 155 | 0.110 |
Why?
|
| von Willebrand Factor | 2 | 2015 | 672 | 0.110 |
Why?
|
| Fluorescence Polarization Immunoassay | 2 | 2005 | 9 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 5 | 2015 | 2154 | 0.110 |
Why?
|
| Infant | 19 | 2011 | 36055 | 0.110 |
Why?
|
| Gonorrhea | 1 | 2017 | 346 | 0.110 |
Why?
|
| Societies | 2 | 2012 | 108 | 0.110 |
Why?
|
| Laboratories, Hospital | 1 | 2014 | 192 | 0.110 |
Why?
|
| Menopause | 7 | 2008 | 1639 | 0.110 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 1995 | 477 | 0.100 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2008 | 747 | 0.100 |
Why?
|
| False Negative Reactions | 2 | 2008 | 573 | 0.100 |
Why?
|
| Heart | 6 | 2012 | 4382 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 3 | 1996 | 1054 | 0.100 |
Why?
|
| History, 20th Century | 2 | 2015 | 2772 | 0.100 |
Why?
|
| Folic Acid | 4 | 2007 | 1309 | 0.100 |
Why?
|
| Tacrolimus | 1 | 1996 | 733 | 0.100 |
Why?
|
| Smell | 1 | 2014 | 259 | 0.100 |
Why?
|
| Keto Acids | 1 | 1992 | 34 | 0.100 |
Why?
|
| Organizational Innovation | 1 | 2015 | 536 | 0.100 |
Why?
|
| Thyroxine | 1 | 1995 | 667 | 0.100 |
Why?
|
| Amlodipine | 1 | 2012 | 84 | 0.100 |
Why?
|
| Drug Stability | 3 | 1998 | 290 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 5 | 1999 | 1628 | 0.100 |
Why?
|
| Myocardial Ischemia | 5 | 2007 | 2108 | 0.100 |
Why?
|
| Endostatins | 1 | 2012 | 168 | 0.100 |
Why?
|
| Biology | 1 | 2014 | 289 | 0.100 |
Why?
|
| Triiodothyronine | 2 | 2008 | 493 | 0.100 |
Why?
|
| Lovastatin | 2 | 2002 | 116 | 0.100 |
Why?
|
| Myocytes, Cardiac | 4 | 2008 | 1655 | 0.100 |
Why?
|
| Pediatrics | 4 | 2007 | 3587 | 0.100 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 222 | 0.090 |
Why?
|
| Isoenzymes | 5 | 2004 | 1686 | 0.090 |
Why?
|
| Solutions | 2 | 2002 | 412 | 0.090 |
Why?
|
| Acute Disease | 12 | 2007 | 7225 | 0.090 |
Why?
|
| Ethics Committees | 1 | 2010 | 51 | 0.090 |
Why?
|
| Protein Isoforms | 3 | 2006 | 1694 | 0.090 |
Why?
|
| Luminescent Measurements | 3 | 2003 | 341 | 0.090 |
Why?
|
| Disease-Free Survival | 6 | 2013 | 6821 | 0.090 |
Why?
|
| Potassium Channel Blockers | 3 | 1996 | 161 | 0.090 |
Why?
|
| Calibration | 5 | 2009 | 814 | 0.090 |
Why?
|
| Tyrosine | 2 | 2006 | 1432 | 0.090 |
Why?
|
| Androgens | 3 | 2007 | 1291 | 0.090 |
Why?
|
| Blood Gas Analysis | 1 | 1992 | 377 | 0.090 |
Why?
|
| Office Visits | 2 | 1993 | 596 | 0.090 |
Why?
|
| Ecuador | 3 | 2013 | 61 | 0.090 |
Why?
|
| Interleukin-18 | 2 | 2012 | 250 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 1995 | 749 | 0.090 |
Why?
|
| Myocardium | 6 | 2006 | 4690 | 0.090 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2012 | 268 | 0.090 |
Why?
|
| History, Ancient | 1 | 2010 | 211 | 0.090 |
Why?
|
| Hyperlipoproteinemia Type II | 2 | 2006 | 393 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2004 | 849 | 0.090 |
Why?
|
| Recurrence | 13 | 2013 | 8426 | 0.090 |
Why?
|
| Radioimmunoassay | 4 | 2001 | 866 | 0.090 |
Why?
|
| Enalapril | 1 | 2012 | 311 | 0.090 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 168 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 2800 | 0.090 |
Why?
|
| Diabetic Nephropathies | 2 | 2008 | 973 | 0.090 |
Why?
|
| Abdominal Fat | 1 | 2012 | 221 | 0.090 |
Why?
|
| Indicators and Reagents | 3 | 2002 | 460 | 0.090 |
Why?
|
| Diabetes Complications | 2 | 2011 | 1317 | 0.090 |
Why?
|
| United Nations | 1 | 2010 | 150 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2013 | 10146 | 0.090 |
Why?
|
| Brachial Artery | 4 | 2004 | 365 | 0.090 |
Why?
|
| Mathematics | 3 | 1997 | 707 | 0.090 |
Why?
|
| Maryland | 4 | 2012 | 275 | 0.080 |
Why?
|
| Protein Precursors | 4 | 2006 | 1133 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 4902 | 0.080 |
Why?
|
| Bilirubin | 3 | 2000 | 437 | 0.080 |
Why?
|
| Societies, Scientific | 1 | 2010 | 220 | 0.080 |
Why?
|
| Immunoglobulin E | 1 | 1995 | 1484 | 0.080 |
Why?
|
| Acute-Phase Proteins | 3 | 2005 | 250 | 0.080 |
Why?
|
| Hormone Replacement Therapy | 5 | 2002 | 754 | 0.080 |
Why?
|
| Physical Fitness | 4 | 2005 | 732 | 0.080 |
Why?
|
| Coronary Thrombosis | 1 | 2012 | 440 | 0.080 |
Why?
|
| Analysis of Variance | 8 | 2010 | 6234 | 0.080 |
Why?
|
| Heart Failure | 7 | 2023 | 11593 | 0.080 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2013 | 1156 | 0.080 |
Why?
|
| Proteomics | 3 | 2014 | 3816 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2005 | 1355 | 0.080 |
Why?
|
| Insulin Resistance | 5 | 2007 | 3941 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 3 | 2004 | 256 | 0.080 |
Why?
|
| Motivation | 1 | 2018 | 1996 | 0.080 |
Why?
|
| Linkage Disequilibrium | 3 | 2009 | 1996 | 0.080 |
Why?
|
| Blood Coagulation | 1 | 1994 | 1149 | 0.080 |
Why?
|
| Blood Donors | 2 | 2001 | 343 | 0.080 |
Why?
|
| Diabetic Ketoacidosis | 1 | 1992 | 253 | 0.080 |
Why?
|
| Apoprotein(a) | 2 | 2006 | 17 | 0.080 |
Why?
|
| Vitamin B 12 | 3 | 2007 | 522 | 0.080 |
Why?
|
| Plagiarism | 1 | 2008 | 22 | 0.080 |
Why?
|
| Trazodone | 1 | 1988 | 68 | 0.080 |
Why?
|
| Type A Personality | 1 | 1987 | 24 | 0.080 |
Why?
|
| Patient Education as Topic | 2 | 2002 | 2307 | 0.080 |
Why?
|
| Apolipoprotein C-III | 2 | 2006 | 208 | 0.080 |
Why?
|
| Age Factors | 9 | 2008 | 18358 | 0.080 |
Why?
|
| Blood Specimen Collection | 3 | 2004 | 238 | 0.070 |
Why?
|
| Solubility | 6 | 2008 | 1088 | 0.070 |
Why?
|
| Program Evaluation | 1 | 1996 | 2492 | 0.070 |
Why?
|
| Information Dissemination | 2 | 2015 | 1129 | 0.070 |
Why?
|
| Behavior, Animal | 2 | 2014 | 1866 | 0.070 |
Why?
|
| Treatment Outcome | 12 | 2023 | 64378 | 0.070 |
Why?
|
| Activities of Daily Living | 2 | 2008 | 2414 | 0.070 |
Why?
|
| Androstane-3,17-diol | 1 | 2007 | 20 | 0.070 |
Why?
|
| Apolipoprotein B-100 | 3 | 2004 | 155 | 0.070 |
Why?
|
| Anticonvulsants | 2 | 1994 | 1881 | 0.070 |
Why?
|
| Thrombosis | 4 | 2008 | 2929 | 0.070 |
Why?
|
| Thyroid Function Tests | 1 | 2008 | 289 | 0.070 |
Why?
|
| Retinol-Binding Proteins | 3 | 1996 | 67 | 0.070 |
Why?
|
| Hyperglycemia | 2 | 2007 | 1368 | 0.070 |
Why?
|
| Carbon Dioxide | 1 | 1992 | 1146 | 0.070 |
Why?
|
| Statistics as Topic | 4 | 2017 | 2359 | 0.070 |
Why?
|
| Siberia | 1 | 2006 | 30 | 0.070 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2013 | 350 | 0.070 |
Why?
|
| Genotype | 11 | 2011 | 12945 | 0.070 |
Why?
|
| Energy Intake | 5 | 2005 | 2127 | 0.070 |
Why?
|
| Mortality | 2 | 2010 | 2886 | 0.070 |
Why?
|
| Frail Elderly | 1 | 2012 | 751 | 0.070 |
Why?
|
| Nuts | 1 | 2009 | 263 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 1724 | 0.070 |
Why?
|
| Apolipoproteins C | 1 | 1986 | 59 | 0.070 |
Why?
|
| Syndrome | 8 | 2007 | 3262 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 2551 | 0.070 |
Why?
|
| Cadmium | 1 | 2008 | 215 | 0.070 |
Why?
|
| Cardiovascular Agents | 2 | 2004 | 839 | 0.070 |
Why?
|
| Dietary Fiber | 3 | 2005 | 759 | 0.070 |
Why?
|
| Ventricular Function, Left | 5 | 2013 | 3858 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2008 | 275 | 0.070 |
Why?
|
| Absorptiometry, Photon | 1 | 2012 | 1735 | 0.070 |
Why?
|
| Dihydrotestosterone | 1 | 2007 | 195 | 0.070 |
Why?
|
| Lung Diseases | 1 | 1996 | 1910 | 0.070 |
Why?
|
| Oxidative Stress | 8 | 2007 | 3099 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 1503 | 0.070 |
Why?
|
| Alanine | 4 | 2007 | 603 | 0.070 |
Why?
|
| Sodium | 3 | 2006 | 1588 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2009 | 3759 | 0.070 |
Why?
|
| Intermittent Claudication | 1 | 2008 | 303 | 0.070 |
Why?
|
| Vitamin B 6 | 1 | 2007 | 233 | 0.070 |
Why?
|
| Retinol-Binding Proteins, Plasma | 2 | 2016 | 94 | 0.070 |
Why?
|
| ABO Blood-Group System | 1 | 2008 | 367 | 0.070 |
Why?
|
| Hospitals, Private | 1 | 2006 | 63 | 0.070 |
Why?
|
| Artifacts | 2 | 2008 | 1897 | 0.060 |
Why?
|
| Myocarditis | 2 | 2007 | 766 | 0.060 |
Why?
|
| Estrogens | 4 | 2007 | 1520 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 3 | 2012 | 2690 | 0.060 |
Why?
|
| Proportional Hazards Models | 10 | 2013 | 12440 | 0.060 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2007 | 275 | 0.060 |
Why?
|
| Cytokines | 3 | 2018 | 7338 | 0.060 |
Why?
|
| Isoproterenol | 1 | 2006 | 394 | 0.060 |
Why?
|
| Sheep | 1 | 2008 | 1441 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2010 | 731 | 0.060 |
Why?
|
| Europe | 3 | 2016 | 3420 | 0.060 |
Why?
|
| Phospholipids | 1 | 2009 | 784 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 4745 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2000 | 4412 | 0.060 |
Why?
|
| Adenoma, Bile Duct | 1 | 1984 | 29 | 0.060 |
Why?
|
| Stroke Volume | 1 | 1999 | 5460 | 0.060 |
Why?
|
| Hyperlipidemia, Familial Combined | 1 | 2004 | 14 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2010 | 2747 | 0.060 |
Why?
|
| Risk Reduction Behavior | 2 | 2009 | 1098 | 0.060 |
Why?
|
| Animals | 21 | 2014 | 167768 | 0.060 |
Why?
|
| Hypopituitarism | 1 | 2007 | 250 | 0.060 |
Why?
|
| Diabetes Mellitus | 7 | 2015 | 5816 | 0.060 |
Why?
|
| Ventricular Function | 1 | 2006 | 406 | 0.060 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2006 | 213 | 0.060 |
Why?
|
| F2-Isoprostanes | 1 | 2004 | 35 | 0.060 |
Why?
|
| Peroxidase | 1 | 2008 | 605 | 0.060 |
Why?
|
| Natriuresis | 1 | 2004 | 105 | 0.060 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2007 | 1730 | 0.060 |
Why?
|
| Vitamin B Complex | 1 | 2007 | 297 | 0.060 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2005 | 111 | 0.060 |
Why?
|
| Malondialdehyde | 1 | 2004 | 111 | 0.060 |
Why?
|
| Antihypertensive Agents | 2 | 2012 | 2016 | 0.060 |
Why?
|
| Fibroblasts | 1 | 1995 | 4087 | 0.060 |
Why?
|
| Placebos | 4 | 2013 | 1661 | 0.060 |
Why?
|
| Women's Health | 3 | 2011 | 2057 | 0.060 |
Why?
|
| Myelin Sheath | 2 | 1987 | 652 | 0.060 |
Why?
|
| Pyridazines | 1 | 2006 | 200 | 0.060 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 1402 | 0.060 |
Why?
|
| Coronary Angiography | 5 | 2008 | 4451 | 0.060 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 1377 | 0.060 |
Why?
|
| Argon | 1 | 2003 | 36 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2004 | 95 | 0.060 |
Why?
|
| Research Personnel | 1 | 2008 | 582 | 0.060 |
Why?
|
| Simvastatin | 1 | 2006 | 351 | 0.060 |
Why?
|
| Polyhydramnios | 1 | 2003 | 41 | 0.060 |
Why?
|
| Phosphotungstic Acid | 2 | 1997 | 6 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2007 | 795 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2012 | 3156 | 0.060 |
Why?
|
| Secondary Prevention | 5 | 2012 | 1474 | 0.060 |
Why?
|
| ROC Curve | 6 | 2009 | 3563 | 0.050 |
Why?
|
| Disease Progression | 6 | 2018 | 13468 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2004 | 238 | 0.050 |
Why?
|
| Blood Urea Nitrogen | 1 | 2003 | 186 | 0.050 |
Why?
|
| Child Mortality | 1 | 2005 | 205 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 1984 | 296 | 0.050 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2004 | 352 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2006 | 703 | 0.050 |
Why?
|
| Hypoglycemic Agents | 4 | 2009 | 3069 | 0.050 |
Why?
|
| Primary Prevention | 2 | 2008 | 1185 | 0.050 |
Why?
|
| Body Constitution | 2 | 2004 | 273 | 0.050 |
Why?
|
| Vitamins | 2 | 2005 | 1632 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2007 | 618 | 0.050 |
Why?
|
| Likelihood Functions | 2 | 2008 | 987 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2010 | 10748 | 0.050 |
Why?
|
| Cardiovascular System | 2 | 2012 | 835 | 0.050 |
Why?
|
| Dietary Carbohydrates | 2 | 2005 | 890 | 0.050 |
Why?
|
| Lipase | 1 | 2005 | 324 | 0.050 |
Why?
|
| Mineral Oil | 1 | 2022 | 22 | 0.050 |
Why?
|
| Selenium | 1 | 2005 | 416 | 0.050 |
Why?
|
| Hamartoma | 1 | 1984 | 235 | 0.050 |
Why?
|
| Kidney Glomerulus | 1 | 2005 | 568 | 0.050 |
Why?
|
| Fructose | 1 | 2004 | 287 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 4 | 2008 | 577 | 0.050 |
Why?
|
| Boston | 3 | 2006 | 9304 | 0.050 |
Why?
|
| Heme | 3 | 2013 | 313 | 0.050 |
Why?
|
| Micronutrients | 1 | 2005 | 381 | 0.050 |
Why?
|
| Leg | 1 | 2007 | 1087 | 0.050 |
Why?
|
| Caloric Restriction | 1 | 2004 | 296 | 0.050 |
Why?
|
| Diagnosis-Related Groups | 1 | 2004 | 449 | 0.050 |
Why?
|
| Eating | 3 | 2001 | 1536 | 0.050 |
Why?
|
| Rats | 10 | 2006 | 23679 | 0.050 |
Why?
|
| Peritoneal Dialysis | 1 | 2003 | 157 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2008 | 3432 | 0.050 |
Why?
|
| Mannose-Binding Lectins | 2 | 2001 | 96 | 0.050 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2022 | 127 | 0.050 |
Why?
|
| Erythrocytes | 3 | 1996 | 2413 | 0.050 |
Why?
|
| Hospitals | 1 | 2015 | 3887 | 0.050 |
Why?
|
| Prevalence | 4 | 2012 | 15651 | 0.050 |
Why?
|
| Peptides | 1 | 2014 | 4341 | 0.050 |
Why?
|
| Survival Rate | 7 | 2019 | 12721 | 0.050 |
Why?
|
| Thoracotomy | 1 | 2003 | 362 | 0.050 |
Why?
|
| Immunoglobulin G | 3 | 2009 | 4540 | 0.050 |
Why?
|
| Metformin | 1 | 2009 | 907 | 0.050 |
Why?
|
| Telomere | 1 | 2008 | 931 | 0.050 |
Why?
|
| Pyridines | 2 | 2006 | 2859 | 0.050 |
Why?
|
| Homocystine | 1 | 2001 | 21 | 0.050 |
Why?
|
| Mitoxantrone | 1 | 2001 | 148 | 0.050 |
Why?
|
| Rats, Inbred SHR | 4 | 2006 | 186 | 0.050 |
Why?
|
| Postural Balance | 1 | 2006 | 617 | 0.050 |
Why?
|
| Pilot Projects | 4 | 2012 | 8553 | 0.050 |
Why?
|
| Societies, Medical | 3 | 2020 | 3891 | 0.050 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2023 | 195 | 0.050 |
Why?
|
| Receptors, Cell Surface | 2 | 2008 | 2825 | 0.050 |
Why?
|
| Diet, Reducing | 1 | 2004 | 485 | 0.050 |
Why?
|
| London | 1 | 2021 | 234 | 0.050 |
Why?
|
| Hawaii | 1 | 2001 | 101 | 0.050 |
Why?
|
| Cystatins | 1 | 2001 | 55 | 0.050 |
Why?
|
| Nurses | 6 | 2006 | 2467 | 0.050 |
Why?
|
| Hyperaldosteronism | 1 | 2004 | 244 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2001 | 132 | 0.050 |
Why?
|
| Enoxaparin | 2 | 2000 | 392 | 0.050 |
Why?
|
| Aging | 4 | 2012 | 8650 | 0.050 |
Why?
|
| Terbutaline | 1 | 2000 | 23 | 0.050 |
Why?
|
| Exercise Tolerance | 1 | 2006 | 830 | 0.050 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2003 | 406 | 0.050 |
Why?
|
| Esophageal Atresia | 1 | 2003 | 217 | 0.050 |
Why?
|
| Hemostasis | 1 | 2003 | 466 | 0.040 |
Why?
|
| Sciatic Nerve | 2 | 1998 | 613 | 0.040 |
Why?
|
| Chylomicrons | 1 | 2000 | 26 | 0.040 |
Why?
|
| Immunochemistry | 3 | 1989 | 119 | 0.040 |
Why?
|
| Receptors, Transferrin | 3 | 2008 | 291 | 0.040 |
Why?
|
| Vasodilation | 3 | 2015 | 960 | 0.040 |
Why?
|
| Latex | 1 | 1999 | 49 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 540 | 0.040 |
Why?
|
| Internet | 1 | 2012 | 3082 | 0.040 |
Why?
|
| Pyrrolidines | 3 | 2007 | 337 | 0.040 |
Why?
|
| Premenopause | 1 | 2004 | 1038 | 0.040 |
Why?
|
| Longitudinal Studies | 6 | 2019 | 14490 | 0.040 |
Why?
|
| Gene Frequency | 4 | 2008 | 3612 | 0.040 |
Why?
|
| Leukocytes | 1 | 2008 | 2025 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2007 | 896 | 0.040 |
Why?
|
| Liver Failure | 1 | 2002 | 249 | 0.040 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2002 | 509 | 0.040 |
Why?
|
| Confidence Intervals | 3 | 2012 | 2925 | 0.040 |
Why?
|
| Zinc | 1 | 2004 | 687 | 0.040 |
Why?
|
| Detergents | 1 | 2000 | 235 | 0.040 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 677 | 0.040 |
Why?
|
| Fluoroquinolones | 3 | 2007 | 308 | 0.040 |
Why?
|
| Surface-Active Agents | 1 | 2000 | 150 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 20500 | 0.040 |
Why?
|
| Iron Overload | 3 | 2008 | 240 | 0.040 |
Why?
|
| Exercise Test | 5 | 2008 | 2121 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2023 | 597 | 0.040 |
Why?
|
| Health | 1 | 2002 | 398 | 0.040 |
Why?
|
| Altitude | 1 | 2000 | 160 | 0.040 |
Why?
|
| Nutrition Assessment | 4 | 2005 | 726 | 0.040 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2010 | 1554 | 0.040 |
Why?
|
| Skinfold Thickness | 1 | 1999 | 158 | 0.040 |
Why?
|
| Bile Duct Neoplasms | 1 | 1984 | 602 | 0.040 |
Why?
|
| Fibrinolytic Agents | 4 | 2004 | 2071 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 6313 | 0.040 |
Why?
|
| Severity of Illness Index | 6 | 2015 | 15785 | 0.040 |
Why?
|
| Motor Activity | 1 | 2009 | 2685 | 0.040 |
Why?
|
| Cause of Death | 2 | 2008 | 3675 | 0.040 |
Why?
|
| Growth Hormone | 1 | 2001 | 568 | 0.040 |
Why?
|
| Receptors, Androgen | 1 | 2005 | 1077 | 0.040 |
Why?
|
| Comorbidity | 6 | 2015 | 10495 | 0.040 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2004 | 812 | 0.040 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2004 | 559 | 0.040 |
Why?
|
| Abdomen | 1 | 2004 | 1129 | 0.040 |
Why?
|
| Cross-Over Studies | 4 | 2008 | 2048 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2007 | 1160 | 0.040 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2000 | 296 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2005 | 7843 | 0.040 |
Why?
|
| Pregnancy | 7 | 2012 | 29742 | 0.040 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2022 | 560 | 0.040 |
Why?
|
| Immune Sera | 1 | 1998 | 613 | 0.040 |
Why?
|
| Tamoxifen | 2 | 2001 | 963 | 0.040 |
Why?
|
| Vitamin E Deficiency | 1 | 1998 | 30 | 0.040 |
Why?
|
| Cyclodextrins | 1 | 1998 | 65 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 4284 | 0.040 |
Why?
|
| Glycemic Index | 3 | 2005 | 393 | 0.040 |
Why?
|
| Renal Dialysis | 2 | 2003 | 1786 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3774 | 0.040 |
Why?
|
| Nuclear Family | 1 | 1999 | 313 | 0.040 |
Why?
|
| Docosahexaenoic Acids | 1 | 2004 | 905 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2016 | 17768 | 0.040 |
Why?
|
| Vasculitis | 1 | 2002 | 522 | 0.040 |
Why?
|
| Phenylcarbamates | 2 | 1994 | 37 | 0.040 |
Why?
|
| Cholesterol, VLDL | 2 | 2004 | 70 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2006 | 1659 | 0.040 |
Why?
|
| Monocytes | 1 | 2007 | 2570 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2005 | 1129 | 0.040 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 1999 | 166 | 0.040 |
Why?
|
| Age Distribution | 3 | 2009 | 2882 | 0.040 |
Why?
|
| Vitamin A Deficiency | 1 | 1998 | 88 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8506 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 2023 | 1155 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2000 | 895 | 0.040 |
Why?
|
| Fathers | 1 | 2000 | 377 | 0.040 |
Why?
|
| Sleep Deprivation | 1 | 2004 | 840 | 0.040 |
Why?
|
| Fruit | 1 | 2002 | 1160 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2003 | 1471 | 0.030 |
Why?
|
| Immunodiffusion | 2 | 1986 | 150 | 0.030 |
Why?
|
| Heart Conduction System | 1 | 2002 | 1011 | 0.030 |
Why?
|
| Magnesium Chloride | 1 | 1996 | 30 | 0.030 |
Why?
|
| Lipoprotein Lipase | 1 | 1997 | 133 | 0.030 |
Why?
|
| Breast Neoplasms | 3 | 2013 | 21017 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2005 | 2125 | 0.030 |
Why?
|
| HIV Infections | 3 | 2005 | 17275 | 0.030 |
Why?
|
| Arousal | 2 | 1994 | 1157 | 0.030 |
Why?
|
| Immunologic Techniques | 2 | 1987 | 213 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 1999 | 625 | 0.030 |
Why?
|
| Cardenolides | 1 | 1995 | 17 | 0.030 |
Why?
|
| Hydrochlorothiazide | 2 | 2006 | 94 | 0.030 |
Why?
|
| Cross Reactions | 2 | 1995 | 818 | 0.030 |
Why?
|
| Prealbumin | 2 | 2008 | 222 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 1996 | 327 | 0.030 |
Why?
|
| Antisickling Agents | 1 | 1996 | 72 | 0.030 |
Why?
|
| Liver Diseases | 2 | 1999 | 1296 | 0.030 |
Why?
|
| Administration, Oral | 6 | 2005 | 3991 | 0.030 |
Why?
|
| Tritium | 1 | 1996 | 707 | 0.030 |
Why?
|
| Acetonitriles | 1 | 1995 | 54 | 0.030 |
Why?
|
| Centrifugation | 1 | 1995 | 122 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 1995 | 74 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 1988 | 2889 | 0.030 |
Why?
|
| Multiple Sclerosis | 2 | 1988 | 3204 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2003 | 3966 | 0.030 |
Why?
|
| Manganese | 1 | 1998 | 395 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1999 | 2470 | 0.030 |
Why?
|
| Lipoproteins, VLDL | 1 | 1996 | 201 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2003 | 1188 | 0.030 |
Why?
|
| Genome, Human | 1 | 2008 | 4416 | 0.030 |
Why?
|
| Brain | 2 | 2016 | 26947 | 0.030 |
Why?
|
| Sampling Studies | 2 | 2008 | 614 | 0.030 |
Why?
|
| Bone Density | 1 | 2008 | 3533 | 0.030 |
Why?
|
| Colitis, Ulcerative | 2 | 2005 | 1919 | 0.030 |
Why?
|
| Mothers | 1 | 2005 | 2189 | 0.030 |
Why?
|
| Weight Loss | 2 | 2004 | 2671 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 2 | 1987 | 513 | 0.030 |
Why?
|
| Weight Gain | 2 | 2005 | 2346 | 0.030 |
Why?
|
| Circadian Rhythm | 3 | 2004 | 2567 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 5129 | 0.030 |
Why?
|
| Crohn Disease | 2 | 2005 | 2275 | 0.030 |
Why?
|
| Mexican Americans | 2 | 2007 | 165 | 0.030 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 1998 | 316 | 0.030 |
Why?
|
| Acetylglucosaminidase | 1 | 1994 | 66 | 0.030 |
Why?
|
| Survival Analysis | 4 | 2008 | 10112 | 0.030 |
Why?
|
| Child Health Services | 1 | 2000 | 644 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 2269 | 0.030 |
Why?
|
| Single-Blind Method | 3 | 2004 | 1570 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2006 | 278 | 0.030 |
Why?
|
| Lactates | 1 | 1995 | 404 | 0.030 |
Why?
|
| Olfactory Mucosa | 1 | 2014 | 99 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2003 | 2092 | 0.030 |
Why?
|
| Tocopherols | 2 | 2004 | 44 | 0.030 |
Why?
|
| Gestational Age | 2 | 2000 | 3565 | 0.030 |
Why?
|
| Prolactin | 1 | 1995 | 621 | 0.030 |
Why?
|
| Young Adult | 7 | 2015 | 58808 | 0.030 |
Why?
|
| Hospitalization | 3 | 2010 | 10652 | 0.030 |
Why?
|
| Cysts | 1 | 1999 | 681 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2004 | 2868 | 0.030 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1995 | 725 | 0.030 |
Why?
|
| Hemolysis | 1 | 1995 | 423 | 0.030 |
Why?
|
| Suburban Population | 1 | 1993 | 53 | 0.030 |
Why?
|
| Acidosis, Lactic | 1 | 1995 | 145 | 0.030 |
Why?
|
| Virginia | 1 | 1993 | 117 | 0.030 |
Why?
|
| Hospital Information Systems | 1 | 1995 | 393 | 0.030 |
Why?
|
| Luteinizing Hormone | 1 | 1995 | 820 | 0.030 |
Why?
|
| Nutritional Status | 2 | 2003 | 1607 | 0.030 |
Why?
|
| Magnetics | 1 | 1996 | 600 | 0.030 |
Why?
|
| HIV-1 | 1 | 1990 | 6850 | 0.030 |
Why?
|
| Free Radicals | 1 | 1993 | 238 | 0.030 |
Why?
|
| Coronary Vessels | 2 | 2004 | 3072 | 0.030 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2008 | 3701 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2006 | 3047 | 0.030 |
Why?
|
| Oxidants | 1 | 1993 | 169 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 1998 | 2672 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2008 | 6493 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2001 | 1090 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 1673 | 0.030 |
Why?
|
| Thrombophilia | 1 | 2015 | 304 | 0.030 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 6293 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 2014 | 392 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 1993 | 211 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2016 | 921 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 1998 | 872 | 0.030 |
Why?
|
| Chromatography | 1 | 1992 | 189 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 1999 | 1475 | 0.030 |
Why?
|
| Oxidation-Reduction | 2 | 2009 | 2221 | 0.030 |
Why?
|
| Maple Syrup Urine Disease | 1 | 1992 | 40 | 0.020 |
Why?
|
| Calcium | 2 | 1995 | 5721 | 0.020 |
Why?
|
| Nerve Block | 1 | 1998 | 688 | 0.020 |
Why?
|
| Argininosuccinic Aciduria | 1 | 1991 | 11 | 0.020 |
Why?
|
| Hospital Administration | 1 | 2015 | 354 | 0.020 |
Why?
|
| Particle Size | 2 | 2009 | 1641 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2012 | 660 | 0.020 |
Why?
|
| Costa Rica | 2 | 2002 | 177 | 0.020 |
Why?
|
| Calcinosis | 1 | 2000 | 1467 | 0.020 |
Why?
|
| Public Health Practice | 2 | 2004 | 218 | 0.020 |
Why?
|
| Genetic Linkage | 2 | 2008 | 2381 | 0.020 |
Why?
|
| Creatine | 2 | 2006 | 426 | 0.020 |
Why?
|
| Anemia | 2 | 2012 | 1504 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1994 | 897 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 261 | 0.020 |
Why?
|
| Tanzania | 2 | 2005 | 1383 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1995 | 1414 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 1995 | 832 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 1994 | 430 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 9404 | 0.020 |
Why?
|
| Biological Transport | 1 | 1995 | 2084 | 0.020 |
Why?
|
| Epinephrine | 1 | 1994 | 790 | 0.020 |
Why?
|
| Kidney | 1 | 2006 | 7016 | 0.020 |
Why?
|
| Sample Size | 1 | 2013 | 838 | 0.020 |
Why?
|
| Commerce | 1 | 2015 | 604 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 2 | 2004 | 999 | 0.020 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1991 | 239 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2023 | 3824 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 1992 | 485 | 0.020 |
Why?
|
| Disability Evaluation | 2 | 2008 | 1825 | 0.020 |
Why?
|
| Lactic Acid | 1 | 1995 | 1133 | 0.020 |
Why?
|
| Dogs | 1 | 2014 | 3840 | 0.020 |
Why?
|
| Sweetening Agents | 1 | 2012 | 290 | 0.020 |
Why?
|
| Insulin, Long-Acting | 1 | 2009 | 58 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2000 | 7818 | 0.020 |
Why?
|
| Diet Surveys | 2 | 2004 | 1161 | 0.020 |
Why?
|
| Metabolism, Inborn Errors | 1 | 1991 | 285 | 0.020 |
Why?
|
| North America | 1 | 2013 | 1276 | 0.020 |
Why?
|
| Australia | 1 | 2013 | 1276 | 0.020 |
Why?
|
| Diastole | 2 | 2002 | 781 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2011 | 2185 | 0.020 |
Why?
|
| Random Allocation | 3 | 2007 | 2385 | 0.020 |
Why?
|
| Succinimides | 1 | 1988 | 81 | 0.020 |
Why?
|
| Physicians | 2 | 2004 | 4580 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 1984 | 4313 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 632 | 0.020 |
Why?
|
| Androstanes | 1 | 2008 | 20 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 3425 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2005 | 1348 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1990 | 463 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 2 | 2006 | 415 | 0.020 |
Why?
|
| Apoproteins | 1 | 1987 | 45 | 0.020 |
Why?
|
| Renin | 1 | 2010 | 635 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 957 | 0.020 |
Why?
|
| Antigens, CD | 3 | 2004 | 3997 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1987 | 299 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1994 | 812 | 0.020 |
Why?
|
| Potassium | 2 | 1995 | 1310 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2001 | 13591 | 0.020 |
Why?
|
| Serum Albumin | 2 | 1988 | 673 | 0.020 |
Why?
|
| Temperature | 1 | 1994 | 2219 | 0.020 |
Why?
|
| Asthma | 2 | 2000 | 6172 | 0.020 |
Why?
|
| Models, Statistical | 2 | 2007 | 5070 | 0.020 |
Why?
|
| Kinetics | 1 | 1995 | 6371 | 0.020 |
Why?
|
| Bronchodilator Agents | 1 | 1990 | 505 | 0.020 |
Why?
|
| Apolipoprotein C-II | 1 | 1986 | 15 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2000 | 4426 | 0.020 |
Why?
|
| Peptidoglycan | 1 | 1989 | 249 | 0.020 |
Why?
|
| Alanine Transaminase | 2 | 2006 | 604 | 0.020 |
Why?
|
| Arthritis, Experimental | 1 | 1989 | 291 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2000 | 3220 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2007 | 6068 | 0.020 |
Why?
|
| Beverages | 1 | 2012 | 819 | 0.020 |
Why?
|
| Apolipoprotein A-II | 1 | 1986 | 41 | 0.020 |
Why?
|
| Massachusetts | 3 | 2007 | 8823 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2010 | 670 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2015 | 2131 | 0.020 |
Why?
|
| Hippurates | 1 | 2006 | 16 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2015 | 1245 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2009 | 597 | 0.020 |
Why?
|
| alpha-Macroglobulins | 1 | 2006 | 60 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2001 | 2210 | 0.020 |
Why?
|
| Maternal Age | 1 | 2009 | 807 | 0.020 |
Why?
|
| Forecasting | 2 | 2010 | 2923 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2008 | 712 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 2904 | 0.020 |
Why?
|
| Taurine | 1 | 2006 | 93 | 0.020 |
Why?
|
| Kidney Diseases | 2 | 2004 | 2083 | 0.020 |
Why?
|
| Dextrans | 1 | 1987 | 573 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2007 | 4113 | 0.020 |
Why?
|
| Methionine | 1 | 2007 | 569 | 0.020 |
Why?
|
| Demyelinating Diseases | 1 | 1987 | 351 | 0.020 |
Why?
|
| Monitoring, Physiologic | 2 | 2004 | 1780 | 0.020 |
Why?
|
| Survival | 1 | 2005 | 160 | 0.020 |
Why?
|
| Plasma | 1 | 2008 | 584 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 5797 | 0.010 |
Why?
|
| Albumins | 1 | 1987 | 575 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 604 | 0.010 |
Why?
|
| Hand Strength | 1 | 2007 | 452 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2008 | 583 | 0.010 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2008 | 409 | 0.010 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 1256 | 0.010 |
Why?
|
| Glycine | 1 | 2007 | 662 | 0.010 |
Why?
|
| Body Weight | 3 | 2003 | 4603 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2009 | 1529 | 0.010 |
Why?
|
| Mice | 3 | 2008 | 81101 | 0.010 |
Why?
|
| Hemoglobins, Abnormal | 1 | 1984 | 119 | 0.010 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2005 | 163 | 0.010 |
Why?
|
| Cell Line | 2 | 1996 | 15591 | 0.010 |
Why?
|
| Hemochromatosis | 1 | 2005 | 174 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 1489 | 0.010 |
Why?
|
| Blood Preservation | 1 | 2004 | 168 | 0.010 |
Why?
|
| Ice | 1 | 2004 | 102 | 0.010 |
Why?
|
| Arthritis | 1 | 1989 | 666 | 0.010 |
Why?
|
| Osteoblasts | 1 | 1989 | 1142 | 0.010 |
Why?
|
| Depression | 1 | 2023 | 8057 | 0.010 |
Why?
|
| Temperance | 1 | 2003 | 87 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1994 | 4159 | 0.010 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 11152 | 0.010 |
Why?
|
| Plasminogen Activators | 1 | 2003 | 199 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1998 | 2420 | 0.010 |
Why?
|
| International Cooperation | 2 | 2000 | 1430 | 0.010 |
Why?
|
| Lysine | 1 | 2007 | 998 | 0.010 |
Why?
|
| Prothrombin | 1 | 2003 | 190 | 0.010 |
Why?
|
| Endothelium | 1 | 2005 | 764 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 1664 | 0.010 |
Why?
|
| Xanthophylls | 1 | 2002 | 94 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 383 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2013 | 1809 | 0.010 |
Why?
|
| Thromboembolism | 1 | 2009 | 996 | 0.010 |
Why?
|
| Liver | 3 | 2005 | 7502 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1993 | 2685 | 0.010 |
Why?
|
| Rural Population | 1 | 1993 | 2254 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 1992 | 2144 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2005 | 590 | 0.010 |
Why?
|
| Respiration Disorders | 1 | 2005 | 367 | 0.010 |
Why?
|
| Coronary Restenosis | 1 | 2005 | 396 | 0.010 |
Why?
|
| Lutein | 1 | 2002 | 122 | 0.010 |
Why?
|
| Diet, Fat-Restricted | 1 | 2004 | 329 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 2717 | 0.010 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2003 | 175 | 0.010 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2003 | 226 | 0.010 |
Why?
|
| Siblings | 1 | 2006 | 824 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1987 | 708 | 0.010 |
Why?
|
| Exons | 1 | 2007 | 2387 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2006 | 8143 | 0.010 |
Why?
|
| Eicosanoids | 1 | 2003 | 278 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 1995 | 18940 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2003 | 15637 | 0.010 |
Why?
|
| Fishes | 1 | 2004 | 601 | 0.010 |
Why?
|
| Anticarcinogenic Agents | 1 | 2002 | 249 | 0.010 |
Why?
|
| Blood Coagulation Factors | 1 | 2003 | 365 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2008 | 1404 | 0.010 |
Why?
|
| False Positive Reactions | 2 | 1998 | 956 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 29915 | 0.010 |
Why?
|
| Chemokines | 1 | 2004 | 961 | 0.010 |
Why?
|
| Food Analysis | 1 | 2001 | 103 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2009 | 2118 | 0.010 |
Why?
|
| Health Personnel | 2 | 2005 | 3312 | 0.010 |
Why?
|
| Systole | 1 | 2002 | 936 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 1338 | 0.010 |
Why?
|
| Length of Stay | 2 | 2008 | 6439 | 0.010 |
Why?
|
| Ankle | 1 | 2003 | 349 | 0.010 |
Why?
|
| Heparin | 1 | 1987 | 1632 | 0.010 |
Why?
|
| Antifibrinolytic Agents | 1 | 2003 | 292 | 0.010 |
Why?
|
| Birth Weight | 1 | 2008 | 2097 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 2005 | 949 | 0.010 |
Why?
|
| Haplotypes | 1 | 2006 | 2764 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 2284 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 981 | 0.010 |
Why?
|
| Retreatment | 1 | 2001 | 596 | 0.010 |
Why?
|
| Rest | 1 | 2004 | 914 | 0.010 |
Why?
|
| Software | 1 | 2014 | 4415 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2008 | 1385 | 0.010 |
Why?
|
| Lung | 1 | 1998 | 9985 | 0.010 |
Why?
|
| Carotenoids | 1 | 2002 | 620 | 0.010 |
Why?
|
| Cystatin C | 1 | 2001 | 270 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2007 | 2676 | 0.010 |
Why?
|
| Oxygen | 2 | 1991 | 4191 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2004 | 12951 | 0.010 |
Why?
|
| Anesthesia, Epidural | 1 | 2001 | 233 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 11070 | 0.010 |
Why?
|
| Heterozygote | 1 | 2006 | 2797 | 0.010 |
Why?
|
| Nonlinear Dynamics | 1 | 2001 | 493 | 0.010 |
Why?
|
| Diarrhea | 1 | 2005 | 1317 | 0.010 |
Why?
|
| Indoles | 1 | 2007 | 1828 | 0.010 |
Why?
|
| Mast Cells | 1 | 2006 | 1390 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1995 | 9160 | 0.010 |
Why?
|
| Ultrasonography | 2 | 2004 | 5952 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1994 | 4777 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 2004 | 1561 | 0.010 |
Why?
|
| Food | 1 | 2003 | 771 | 0.010 |
Why?
|
| TRPP Cation Channels | 1 | 1999 | 177 | 0.010 |
Why?
|
| Antibodies | 1 | 2006 | 2420 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2001 | 1172 | 0.010 |
Why?
|
| Models, Biological | 2 | 2007 | 9460 | 0.010 |
Why?
|
| Heart Rate | 2 | 2004 | 4166 | 0.010 |
Why?
|
| Myocardial Revascularization | 1 | 2001 | 792 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 2189 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2019 | 80168 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 972 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1998 | 426 | 0.010 |
Why?
|
| Apnea | 1 | 1998 | 195 | 0.010 |
Why?
|
| Blood Sedimentation | 1 | 1998 | 234 | 0.010 |
Why?
|
| Pericardium | 1 | 2001 | 674 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 2003 | 1345 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 3671 | 0.010 |
Why?
|
| Papio | 1 | 1998 | 661 | 0.010 |
Why?
|
| Hyperoxia | 1 | 1998 | 250 | 0.010 |
Why?
|
| Homeostasis | 1 | 2007 | 3301 | 0.010 |
Why?
|
| Walking | 1 | 2003 | 1188 | 0.010 |
Why?
|
| Causality | 1 | 2002 | 1241 | 0.010 |
Why?
|
| Demography | 1 | 2000 | 1651 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 2640 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 1987 | 1926 | 0.010 |
Why?
|
| Progesterone | 1 | 1999 | 742 | 0.010 |
Why?
|
| Nociceptors | 1 | 1998 | 457 | 0.010 |
Why?
|
| Succimer | 1 | 1994 | 31 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2005 | 2907 | 0.010 |
Why?
|
| Anesthesia, General | 1 | 2001 | 1165 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 1994 | 115 | 0.010 |
Why?
|
| Technetium Tc 99m Dimercaptosuccinic Acid | 1 | 1994 | 81 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2004 | 1494 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1994 | 129 | 0.010 |
Why?
|
| Data Collection | 1 | 2003 | 3322 | 0.010 |
Why?
|
| Anorexia | 1 | 1994 | 154 | 0.010 |
Why?
|
| Disease Models, Animal | 3 | 1998 | 18119 | 0.010 |
Why?
|
| Aortic Aneurysm | 1 | 1998 | 648 | 0.010 |
Why?
|
| Child Development | 1 | 2005 | 2285 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 6520 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2006 | 3533 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1994 | 367 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 1994 | 221 | 0.010 |
Why?
|
| Charcoal | 1 | 1992 | 66 | 0.010 |
Why?
|
| Epilepsy, Generalized | 1 | 1994 | 178 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2004 | 3806 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 8530 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 1793 | 0.010 |
Why?
|
| Prednisolone | 1 | 1992 | 326 | 0.010 |
Why?
|
| Psychophysiology | 1 | 1991 | 136 | 0.010 |
Why?
|
| Theophylline | 1 | 1990 | 131 | 0.010 |
Why?
|
| Physical Education and Training | 1 | 1991 | 100 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 1991 | 318 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2007 | 4652 | 0.010 |
Why?
|
| Ammonia | 1 | 1991 | 236 | 0.010 |
Why?
|
| Chronic Disease | 2 | 1999 | 9267 | 0.010 |
Why?
|
| Patient Selection | 1 | 2002 | 4244 | 0.010 |
Why?
|
| Safety | 1 | 1994 | 1147 | 0.010 |
Why?
|
| Apoptosis | 1 | 2006 | 9468 | 0.010 |
Why?
|
| Erythrocyte Aging | 1 | 1989 | 53 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 3069 | 0.010 |
Why?
|
| Verbal Behavior | 1 | 1991 | 335 | 0.010 |
Why?
|
| Flame Ionization | 1 | 1988 | 2 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1990 | 638 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1989 | 139 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2008 | 12604 | 0.010 |
Why?
|
| Imidazoles | 1 | 1995 | 1179 | 0.010 |
Why?
|
| Cytosol | 1 | 1992 | 886 | 0.000 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1989 | 144 | 0.000 |
Why?
|
| Estrogen Antagonists | 1 | 1989 | 151 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1994 | 2020 | 0.000 |
Why?
|
| Aerosols | 1 | 1990 | 631 | 0.000 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1989 | 410 | 0.000 |
Why?
|
| Wallerian Degeneration | 1 | 1987 | 68 | 0.000 |
Why?
|
| Rats, Inbred Lew | 1 | 1989 | 1154 | 0.000 |
Why?
|
| Phenotype | 1 | 2004 | 16534 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1989 | 1433 | 0.000 |
Why?
|
| Fever | 1 | 1994 | 1617 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1989 | 865 | 0.000 |
Why?
|
| Respiratory Function Tests | 1 | 1990 | 1680 | 0.000 |
Why?
|
| Electrolytes | 1 | 1986 | 274 | 0.000 |
Why?
|
| Amino Acids | 1 | 1991 | 1713 | 0.000 |
Why?
|
| Rheumatic Diseases | 1 | 1992 | 639 | 0.000 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 1994 | 1079 | 0.000 |
Why?
|
| Oxygen Consumption | 1 | 1991 | 1845 | 0.000 |
Why?
|
| Mice, Transgenic | 1 | 1995 | 9518 | 0.000 |
Why?
|
| Prostatic Hyperplasia | 1 | 1986 | 530 | 0.000 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1997 | 3603 | 0.000 |
Why?
|
| Receptors, Estrogen | 1 | 1989 | 2210 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1989 | 11471 | 0.000 |
Why?
|